New York State Common Retirement Fund Boosts Stake in Intercept Pharmaceuticals, Inc. (ICPT)

New York State Common Retirement Fund increased its position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 13.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 40,300 shares of the biopharmaceutical company’s stock after purchasing an additional 4,799 shares during the period. New York State Common Retirement Fund owned 0.16% of Intercept Pharmaceuticals worth $4,879,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. US Bancorp DE purchased a new stake in shares of Intercept Pharmaceuticals in the 1st quarter valued at about $130,000. IFP Advisors Inc lifted its holdings in shares of Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 730 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter valued at about $212,000. PNC Financial Services Group Inc. lifted its holdings in shares of Intercept Pharmaceuticals by 0.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 14 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter valued at about $235,000. 82.19% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently weighed in on ICPT shares. Wedbush reissued an “outperform” rating and issued a $231.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, June 23rd. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Jefferies Group LLC began coverage on Intercept Pharmaceuticals in a research note on Monday, July 10th. They set a “buy” rating and a $275.00 price objective for the company. Zacks Investment Research raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price objective for the company in a research note on Tuesday, July 11th. Finally, Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price objective (up from $60.00) on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $153.76.

In other Intercept Pharmaceuticals news, Director Daniel G. Welch sold 217 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total value of $27,506.92. Following the transaction, the director now owns 3,710 shares in the company, valued at $470,279.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Mark Pruzanski sold 1,532 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,278 shares of company stock worth $592,796. 4.50% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “New York State Common Retirement Fund Boosts Stake in Intercept Pharmaceuticals, Inc. (ICPT)” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://sportsperspectives.com/2017/10/16/new-york-state-common-retirement-fund-boosts-stake-in-intercept-pharmaceuticals-inc-icpt.html.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at 65.49 on Monday. Intercept Pharmaceuticals, Inc. has a one year low of $54.98 and a one year high of $147.52. The firm’s market cap is $1.64 billion. The firm’s 50-day moving average price is $85.96 and its 200-day moving average price is $108.58.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The firm’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($3.14) earnings per share. Equities research analysts expect that Intercept Pharmaceuticals, Inc. will post ($13.99) earnings per share for the current fiscal year.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply